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Part of the Cardiologist’s Complete Blood Count?*John W. Eikelboom, MBBS,y Theodore E. Warkentin, MDyzSEE PAGE 2122C linicians have had a longstanding interest inthe use of immature cell counts as a diag-nostic and prognostic tool. Methods for
measuring immature red cells (reticulocytes) are
widely available, and an elevated reticulocyte count
is routinely used as a marker of increased red cell pro-
duction (e.g., hemolysis). Alterations in the immature
platelet count (IPC) offer similar potential for insight
into platelet disorders, but advances in this area
have been limited by the lack of simple, widely appli-
cable laboratory methods to measure IPC.
The recent advent of automated whole blood
methods has stimulated interest in the measurement
of the IPC (1). Following the addition of nucleic acid–
speciﬁc dyes to whole blood and sorting by cell size
and ribonucleic acid content, IPC can be calculated by
multiplying the percentage of immature platelets by
the platelet count. Most of the research using auto-
mated IPC methods has focused on assessing platelet
turnover in different types of thrombocytopenia, but
multiple reports also have indicated that increased
IPC is associated with a reduced response to anti-
platelet therapy (2–4).
In this issue of the Journal, Ibrahim et al. (5) report
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contents of this paper to disclose.association between IPC and the risk for subsequent
major adverse cardiovascular events (MACE), deﬁned
as a composite of death, myocardial infarction, un-
planned revascularization, or recurrent angina, in 93
adults with coronary artery disease (CAD) receiving
oral antiplatelet therapy (5). The 30 patients who
experienced MACE during the median follow-up of 31
months had a signiﬁcantly greater mean baseline IPC
value than did the 59 who did not experience MACE
(10,507 vs. 6,322 platelets/ml; p ¼ 0.002). Moreover,
60% of patients in the upper tertile of IPC experi-
enced MACE compared with 24.1% in the intermedi-
ate tertile and 16.7% in the lower tertile (p < 0.001).
Time-dependent receiver operating characteristic
curve analysis demonstrated that a cut point of 7,632
platelets/ml was 70.7% sensitive and 82.1% speciﬁc for
MACE, and the Cox proportional hazards analysis
demonstrated that after adjustment for potential
confounding variables, IPC >7,632 platelets/ml re-
mained associated with a >4-fold increased risk for
MACE (hazard ratio: 4.65; 95% conﬁdence interval:
1.78 to 12.16; p < 0.002).Why might a higher IPC be associated with
greater risk for MACE in patients with CAD receiving
antiplatelet therapy? Several possible explanations
should be considered (Figure 1). First, immature pla-
telets are larger and enzymatically and metaboli-
cally more active, and have a higher thrombotic
potential than smaller platelets (6). Consistent with
this conclusion, greater mean platelet volume has
been linked with the future risk for cardiovascular
events in healthy subjects, in patients with cardio-
vascular risk factors, and in those with a history of
myocardial infarction (7).
Second, a reduced response to antiplatelet ther-
apy in patients with increased IPC could explain
the link with the risk for MACE. Aspirin inhibits
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FIGURE 1 Possible Explanations for the Association
Between IPC and the Risk for MACE
If the association is causal, interventions that target immature
platelet count (IPC) might lower the risk for major adverse
cardiovascular events (MACE), whereas if the association is
confounded, interventions that target IPC cannot be expected to
affect the risk for MACE.
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2131platelet activation by irreversibly acetylating platelet
cyclooxygenase (COX)-1, thereby preventing the for-
mation of thromboxane A2, a powerful platelet
agonist and vasoconstrictor. Although aspirin itself
has a half-life of only 20 min, it produces near-
complete inhibition of thromboxane A2 synthesis for
24 h when given once daily because platelets are
anucleate and unable to regenerate COX-1 (8). In most
patients receiving long-term, once-daily aspirin,
platelet COX-1 activity is restored at a rate of
approximately 10% per day, reﬂecting the 10-day
platelet life span and the entry into the circulation of
10% of newly formed platelets. The inhibition of at
least 90% of circulating platelets is sufﬁcient to
maintain complete suppression of platelet function.
In situations of increased platelet turnover, however,
a signiﬁcant proportion of platelets are unaffected by
aspirin and thus retain the capacity to produce
thromboxane and to aggregate. Similarly, a signiﬁ-
cant proportion of platelets are unaffected by clopi-
dogrel in patients with increased platelet turnover.
Third, the association between IPC and MACE
might be explained by confounding. In the study by
Ibrahim et al. (5), patients who experienced MACE
might have had more advanced atherosclerosis and
higher blood levels of inﬂammatory markers than
those who did not experience MACE. Elevated blood
levels of inﬂammatory markers have been linked with
increased blood levels of thrombopoietin, the primary
regulator of platelet turnover (9). Thus, the increasein IPC might be a consequence of more advanced
atherosclerosis rather than playing a causal role.
What are the implications of these ﬁndings for
clinical practice? As pointed out by Ibrahim et al. (5),
IPC is an easily obtained, simple, and inexpensive
laboratory test that has the potential to be readily
incorporated into clinical practice. However, we think
it would be premature to conclude that measurement
of the IPC is ready for routine application to cardio-
vascular risk prediction or to therapeutics. Numerous
biochemical markers (e.g., D-dimer, mean platelet
volume, homocysteine) are independently predictive
of future cardiovascular events, but before being
introduced into practice, we need evidence that
measuring the marker will beneﬁt patients. Proof
that IPC is causally linked with future cardiovascular
risk requires demonstration that the association
is modiﬁable, for example, by showing that more
frequently administered or more potent antiplatelet
therapies produce greater and more sustained
platelet blockade than does standard therapy in pa-
tients with high platelet turnover, and that this
translates into a reduction in cardiovascular events.
Preliminary studies have demonstrated that twice-
daily compared with once-daily aspirin administra-
tion produces greater platelet inhibition in patients
with diabetes and increased platelet turnover (10),
but whether this translates into superior cardiovas-
cular protection remains to be demonstrated. A more
immediate clinical application of IPC outside of the
cardiovascular realm is for the workup of thrombo-
cytopenia to distinguish decreased marrow produc-
tion from increased peripheral destruction as a cause
for low platelet count.
Although routine IPC measurement is not yet
“ready for prime time,” the ability to rapidly measure
IPC presents an opportunity for intensiﬁed research
into the mechanisms by which elevated IPC confers
increased cardiovascular risk. The ﬁndings by Ibra-
him et al. (5) ﬁrst need to be replicated with larger
numbers of patients to obtain more robust estimates
of the magnitude of the association between IPC and
the risk for MACE. We also need to explore other
clinical settings in which the potential exists for
increased platelet turnover and reduced response to
antiplatelet therapy. Affected patient populations can
then be studied with interventions that reduce the
IPC or more effectively suppress immature platelets
with the aim of reducing cardiovascular risk.
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